Table 2 Main characteristics of the individual studies analyzed on the systematic review and meta-analysis.
Marker | Article | JCR | Location | Design | Aim of the Study | STROBE |
|---|---|---|---|---|---|---|
CD82 | Nishioka et al. (Int J Cancer 2013) | 5.085 | Japan | Cross-sectional observational | Analyze the protein expression profile of CD34+/CD38− AML cells and compare it with the expression profile of their CD34+/CD38+ counterparts using isobaric tags for relative and absolute quantitation (iTRAQ) and explored the function of CD82 in CD34+/CD3− AML cells in vitro as well as in vivo. | 17 (77.8%) |
CD82 | Nishioka et al. (Int J Cancer 2014) | 5.085 | Japan | Cross-sectional observational | Explore the regulation of STAT5/IL-10 by CD82 and its impact on the survival of CD34+/CD38− AML cells. | 17 (77.8%) |
CD87 | Atfy et al. (Med Oncol 2012) | 2.634 | Germany | Cohort | Assess the prognostic significance of pretreatment detection of CD87 and the prevalence of its expression and value as a predictor for survival. | 20 (91%) |
CD93 | Iwasaki et al. (Cell Stem Cell 2015) | 22.268 | USA | Cross-sectional observational | Report that the cell surface lectin CD93 is a functional marker of LSCs in a specific genetic subtype of AML with rearrangements of the MLL gene. | 20 (91%) |
CD135 | Sharawat et al. (Cytometry B 2013) | 2.398 | India | Cohort | Evaluate clinical significance of FLT3 (CD135) and c-KIT (CD117) coexpression on myeloblasts in AML. | 21 (95.4%) |
CXCR4 | Mannelli et al. (Cytometry B 2014) | 2.398 | Italy | Cohort | Investigate the expression of connexins in primary human AML cells derived from unselected patients | 21 (95.4%) |
CD133 | Tolba et al. (Med Oncol 2013) | 2.634 | USA | Cohort | Assess CD133 expression in patients with acute myeloid or lymphoblastic leukemia and to evaluate its correlation with the different clinical and laboratory data as well as its relation to disease outcome. | 20 (91%) |
TRAILR2 (CD262) | Schmohl et al. (Anticancer research 2015) | 1.826 | Germany | Cohort | Evaluate the association of co-expression of TRAILR1-3, TNFR1 and FAS on AML blasts at first diagnosis with different AML subtypes and risk groups and to combine with clinical data in order to evaluate their prognostic and clinical significance. | 21 (95.4%) |
TRAILR3 (CD263) | ||||||
TNFR1 | ||||||
ILT3 | Dobrowolska et al. (Cytometry B 2013) | 2.398 | USA | Cross-sectional observational | Investigated ILT3 expression by normal and leukemic myeloid precursors. We report that ILT3 expression identifies normal hematopoietic precursors committed to the monocytic lineage and that ILT3 is a reliable marker that distinguishes AML with monocytic differentiation from other types of AML | 19 (86.4%) |
hMICL | Larsen et al. (Cytometry B 2012) | 2.398 | United Kingdom | Case control | Based on data from stem cell research, they hypothesized that the human inhibitory C-type lectin like receptor (hMICL) might represent a novel diagnostic and prognostic vehicle in a standard flow cytometry (FCM) setting. | 20 (91%) |
CD90 | Chávez-gonzález et al. (Arc Med Res 2014) | 2.645 | Mexico | Case control | Analyze the expression of CD90, CD96, CD117, and CD123 on CD34+ CD38− cells, CD34+ CD38+ cells and CD34- CD38+ cells. | 21 (95, 4%) |
CD96 |
